Geneva, Oct. 27 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134565) titled 'Clinical Study of Response to PARP Inhibitor Therapy in Patients with BRCA-Mutated Epithelial Ovarian Cancer' on Oct. 16.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Peking University Third Hospital
Condition:
BRCA-Mutated Ovarian Cancer
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-10-16
Target Sample Size: Observation group:1200;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=347785
Disclaimer: Curated by HT Syndication....